Medical Firm Genesis MedTech Weighs Up to $500 Million HK IPO, Sources Say

Genesis MedTech Group, a medical device company, has selected advisers for a potential initial public offering in Hong Kong, according to people familiar with the matter.

(Bloomberg) — Genesis MedTech Group, a medical device company, has selected advisers for a potential initial public offering in Hong Kong, according to people familiar with the matter.

The Singapore-based firm is working with Citic Securities Co., Goldman Sachs Group Inc. and Morgan Stanley on the proposed listing, which could take place as early as next year, the people said. Genesis could raise as much as $500 million in the IPO, though it could be significantly smaller depending on market conditions, one of the people said, asking not to be identified because the matter is private.

The company had weighed launching the first-time share sale this year, but decided to wait, one of the people said. Companies in the Asian financial hub have raised just $2.9 billion via IPOs this year, down from $4.7 billion a year ago, according to data compiled by Bloomberg. Indonesia, traditionally a less active market than Hong Kong in terms of IPO volume, has seen companies raise $2.92 billion this year.

Considerations are preliminary and details of the offering including size and timeline could still change, the people said. Representatives for Citic Securities, Goldman Sachs and Morgan Stanley declined to comment.

Genesis doesn’t have a specific IPO timeline or fundraising amount in mind, a company spokesperson said in response to a Bloomberg News query.

Founded in 2019, Genesis’s product portfolio focuses on value-segment, multi-therapy medical device products for emerging markets, according to a press release announcing the completion of its series B fundraising in 2021. The round was led by General Atlantic with participation from firms including Citic Capital.

The company’s products include minimally invasive surgical devices, neurovascular devices for stroke prevention, diagnosis and treatment, and others in the cardiovascular and peripheral vascular fields, its website shows.

–With assistance from Elffie Chew.

(Updates with Genesis response in fifth paragraph.)

More stories like this are available on bloomberg.com